Effects of Afatinib on Development of Non-Small-Cell Lung Cancer by Regulating Activity of Wnt/β-Catenin Signaling Pathway

Lung cancer has been one of the deadliest cancers in the world. Afatinib is an ErbB family irreversible blocker that was authorized by the FDA and EMA in 2013 for the treatment of advanced EGFR mutation-positive NSCLC. Therefore, we aim to discover the impact of Afatinib on the development of non-sm...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yue, Zhang, Jiajing, Yun, Changping, Dong, Chenchen, Tian, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256313/
https://www.ncbi.nlm.nih.gov/pubmed/35799670
http://dx.doi.org/10.1155/2022/5213016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256313/
https://www.ncbi.nlm.nih.gov/pubmed/35799670
http://dx.doi.org/10.1155/2022/5213016

Ejemplares similares